7Suppliers
5Customers
2Debt Items
11Related Chains

Source-Backed Evidence Depth

LB Pharmaceuticals Inc (LBRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships
2Distinct source URLs
11High confidence
0.795Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

LB Pharmaceuticals Inc Suppliers

TickerNameConfidenceEvidence
EXTERNAL-VENDORS-AND-CROS EXTERNAL-VENDORS-AND-CROS 90% This model includes internal teams and systems as well as external vendors and CROs to comprise a full clinical trial team.
THIRD-PARTIES THIRD-PARTIES 85% We also rely on third parties to provide other products, services, parts, or otherwise to operate our business, including with respect to our cybersecurity infrastructure.
ANDREW-VAINO ANDREW-VAINO 80% In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
ANDREW-VAINO-PH-D ANDREW-VAINO-PH-D 80% In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
MARC-PANOFF MARC-PANOFF 80% In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
ZACHARY-PRENSKY ZACHARY-PRENSKY 80% In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing investors, co-founders, former and current directors, and form…
NBP NovaBridge Biosciences 72% Reciprocal relationship from NBP graph: Reciprocal relationship from LBRX graph: Reciprocal relationship from NBP graph: Reciprocal relationship from LBRX graph: Reciprocal relationship from NBP grap…

LB Pharmaceuticals Inc Customers

TickerNameConfidenceEvidence
LICENSEES-OF-LB-102 LICENSEES-OF-LB-102 90% Net sales are defined in these agreements as the gross payments received on total commercial sales of LB-102 less certain standard deductions, whether received by us or any licensee of LB-102.
HOLDERS-OF-FUTURE-ROYALTIES HOLDERS-OF-FUTURE-ROYALTIES 80% As of March 31, 2026, certain of our former and current officers and their affiliates held 1.13% of the future royalties.
CEREVEL-THERAPEUTICS-HOLDINGS-INC CEREVEL-THERAPEUTICS-HOLDINGS-INC 62% take steps toward our goal of being an integrated biopharmaceutical company capable of supporting commercial activities, including establishing sales, marketing and distribution infrastructure; • att…
DELAWARE-GENERAL-CORPORATION DELAWARE-GENERAL-CORPORATION 62% sdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area, or EEA, and the UK have significant…
EMERGING-GROWTH-COMPANY EMERGING-GROWTH-COMPANY 62% the stock option grants. The comparable companies were chosen based on their size, stage of their life cycle, or area of specialty. We will continue to apply this process until enough historical info…

LB Pharmaceuticals Inc Debt Obligations

InstrumentDescriptionConfidenceEvidence
LBRX-DEBT-10624 Warrants outstanding: 247000 90% xbrl warrant detail from xbrl 2025-12-31.
LBRX-DEBT Debt stack $3.5M 90% Market cache reports total debt of $3.5M.

LB Pharmaceuticals Inc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for LB Pharmaceuticals Inc.

LB Pharmaceuticals Inc Ownership

HolderNameConfidenceEvidence
LBRX-OWNER-DEEP-TRACK-CAPITAL-LP Deep Track Capital, LP 90% 13F overlay lists Deep Track Capital, LP as top holder; 77 tracked holders.

LB Pharmaceuticals Inc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
EH EHang Holdings Limited 100.00 2
ABT Abbott Laboratories 100.00 2
BMY Bristol-Myers Squibb Company 100.00 2
BMYMP Bristol-Myers Squibb Co 100.00 2
EM Smart Share Global Limited 100.00 2
JNJ Johnson & Johnson 100.00 2
PRE Prenetics Global Limited 100.00 2
SNYNF Sanofi 100.00 2
NMRA Neumora Therapeutics, Inc. 100.00 2
SBMFF Sino Biopharmaceutical Limited 100.00 2
NBP NovaBridge Biosciences 36.29 1 ['supplier']
🔐
LBRX
Unlock LBRX Supply Chain Data
Verified relationships include:
EXTERNAL-VENDORS-AND-CROSEXTERNAL-VENDORS-AND-CROSSupplier90%
THIRD-PARTIESTHIRD-PARTIESSupplier85%
LICENSEES-OF-LB-102LICENSEES-OF-LB-102Customer90%
HOLDERS-OF-FUTURE-ROYALTIESHOLDERS-OF-FUTURE-ROYALTIESCustomer80%
+11 more relationships locked
Subscribe — View plans →